The IPSS-R has prognostic impact in untreated patients with MDS del(5q).
暂无分享,去创建一个
K. Götze | R. Latagliata | P. Fenaux | P. Valent | M. Pfeilstöcker | U. Germing | J. Kaivers | R. Haas | U. Platzbecker | N. Gattermann | D. Haase | C. Ganster | A. Kündgen | B. Hildebrandt | G. Bug | M. Lauseker | E. Olíva | B. Xicoy
[1] In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time , 2015, British journal of haematology.
[2] R. Schlenk,et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. , 2014, Leukemia research.
[3] A. Glasmacher,et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis , 2012, Leukemia.
[4] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[5] Z. Agur,et al. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database , 2012, American journal of hematology.
[6] R. Schlenk,et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.
[7] A. Carrió,et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support , 2011, American journal of hematology.
[8] C. Steidl,et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.
[9] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.